Erratum: Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy (NCI: Journal of the National Cancer Institute (2007) 99:9 (727–737) DOI: 10.1093/jnci/djk154);Tamoxifen for the prevention of breast cancer: Late results of the Italian randomized tamoxifen prevention trial among women with hysterectomy

Journal of the National Cancer Institute

Volumn 99, Issue 9, 2007, Pages 727-737

  Veronesi, Umberto ^a   Maisonneuve, Patrick ^a   Rotmensz, Nicole ^a   Bonanni, Bernardo ^a   Boyle, Peter ^c   Viale, Giuseppe ^a,b   Costa, Alberto ^d   Sacchini, Virgilio ^a,e   Travaglini, Roberto ^f   D'Aiuto, Giuseppe ^g   Oliviero, Pasquale ^g   Lovison, Francesco ^h   Gucciardo, Giacomo ⁱ   del Turco, Marco Rosselli ^j   Muraca, Maria Grazia ^j   Pizzichetta, Maria Antonietta ^k   Conforti, Serafino ^l   Decensi, Andrea ^a,m  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d IRCCS   (Italy)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f Comitato Prevenzione Tumori al seno ^*  (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h Lega Italiana per la lotta contro i tumori   (Italy)

ⁱ SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^j CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^k CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^l Ospedale di Cosenza   (Italy)

^m GALLIERA HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HORMONE RECEPTOR; PLACEBO; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ANGINA PECTORIS; ANXIETY; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DEEP VEIN THROMBOSIS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ESTROGEN THERAPY; EYE DISEASE; FEMALE; FEMALE SEXUAL DYSFUNCTION; FLUID RETENTION; FOLLOW UP; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYSTERECTOMY; ITALY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; NAUSEA; OVARIECTOMY; PATIENT SELECTION; PHLEBITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA VEIN OCCLUSION; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN DISEASE; STOMACH DISEASE; STROKE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; URINARY TRACT DISEASE; URINE INCONTINENCE; VAGINA DISCHARGE; VAGINAL DRYNESS; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; VOMITING; WEIGHT GAIN; BREAST TUMOR; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RISK ASSESSMENT; TIME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; INCIDENCE; ITALY; MIDDLE AGED; OVARIECTOMY; PLACEBOS; RISK ASSESSMENT; TAMOXIFEN; TIME FACTORS;

EID: 34249732092     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djae093     Document Type: Erratum

References (38)

1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
2. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 1998; 352:98-101.
3. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, et al. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 1998;352:93-7.
4. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
5. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295: 2727-41.
6. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattsson A, Silfversward C, et al. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989;1:117-20.
7. Veronesi U, Maisonneuve P, Sacchini V, Rotmensz N, Boyle P. Tamoxifen for breast cancer among hysterectomised women. Lancet 2002;359: 1122-4.
8. Veronesi U, Maisonneuve P, Rotmensz N, Costa A, Sacchini V, Travaglini R, et al. Italian randomized trial among women with hysterectomy:tAmoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:160-5.
9. Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005;330:932.
10. Decensi A, Maisonneuve P, Rotmensz N, Bettega D, Costa A, Sacchini V, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005;111:650-6.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
12. Regan MM, Viale G, Mastropasqua MG, Maiorano E, Golouh R, Carbone A, et al.; International Breast Cancer Study Group. Re-evaluating adjuvant breast cancer trials: Assessing hormone receptor status by immunohistochemical versus extraction assays. J Natl Cancer Inst 2006;98: 1571-81.
13. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, et al. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: A study of preoperative treatment. Clin Cancer Res 2004;10:6622-8.
14. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62.
15. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 1989;81:1879-86.
16. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst 1999;91:1541-8.
17. Vogel VG, Lo S. Preventing hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst 2003;95:91-3.
18. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
19. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003;348:1839-54.
20. Decensi A, Galli A, Veronesi U. HRT opposed to low-dose tamoxifen (HOT study): Rationale and design. Recent Results Cancer Res 2003; 163:104-11.
21. Olson JE, Sellers TA, Iturria SJ, Hartmann LC. Bilateral oophorectomy and breast cancer risk reduction among women with a family history. Cancer Detect Prev 2004;28:357-60.
22. Gronwald J, Tung N, Foulkes WD, Offit K, Gershoni R, Daly M, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 2006;18:2281-4.
23. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Onool 2005;23:9312-8.
24. Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P, et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: Data from the Italian Tamoxifen Trial. J Clin Oncol 2006;24:3708-9.
25. Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2742-51.
26. Waetjen LE, Brown JS, Modelska K, Blackwell T, Vittinghoff E, Cummings SR. Effect of raloxifene on urinary incontinence: A randomized controlled trial. Obstet Gynecol 2004;103:261-6.
27. Powles TJ. Prevention of migrainous headaches by tamoxifen. Lancet 1986;2:1344.
28. O'Dea JP, Davis EH. Tamoxifen in the treatment of menstrual migraine. Neurology 1990;40:1470-1.
29. Silberstein SD. Sex hormones and headache. Rev Neurol (Paris) 2000;156(Suppl 4):4S30-41.
30. Brandes JL. The influence of estrogen on migraine: A systematic review. JAMA 2006;295:1824-30.
31. Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis - part 2. Headache 2006;46: 365-86.
32. Martin VT, Behbehani M. Ovarian hormones and migraine headache: understanding mechanisms and pathogenesis - part I. Headache 2006;46:3-23.
33. Allais G, Bussone G, De Lorenzo C, Mana O, Benedetto C. Advanced strategies of short-term prophylaxis in menstrual migraine: State of the art and prospects. Neurol Sci 2005;26(Suppl 2):S125-9.
34. Andrews M, Nelson BP. Atrial fibrillation. Mt Sinai J Med 2006;73: 482-92.
35. Colls BM, George PM. Severe hypertriglyceridaemia and hypercholesterolaemia associated with tamoxifen use. Clin Oncol (R Coll Radiol) 1998; 10:270-1.
36. Elisaf MS, Nakou K, Liamis G, Pavlidis NA. Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. Ann Oncol 2000;11:067-9.
37. Hozumi Y, Kawano M, Miyata M. Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. Endocr J 1997;44: 745-9.
38. Liu CL, Yang TL. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat 2003;79:11-6.